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Abstract
Background: Laboratory studies have suggested that antibiotic resistance may result in decreased fitness in the bacteria
that harbor it. Observational studies have supported this, but due to ethical and practical considerations, it is rare to have
experimental control over antibiotic prescription rates.
Methods and Findings: We analyze data from a 54-month longitudinal trial that monitored pneumococcal drug resistance
during and after biannual mass distribution of azithromycin for the elimination of the blinding eye disease, trachoma.
Prescription of azithromycin and antibiotics that can create cross-resistance to it is rare in this part of the world. As a result,
we were able to follow trends in resistance with minimal influence from unmeasured antibiotic use. Using these data, we fit
a probabilistic disease transmission model that included two resistant strains, corresponding to the two dominant modes of
resistance to macrolide antibiotics. We estimated the relative fitness of these two strains to be 0.86 (95% CI 0.80 to 0.90),
and 0.88 (95% CI 0.82 to 0.93), relative to antibiotic-sensitive strains. We then used these estimates to predict that, within 5
years of the last antibiotic treatment, there would be a 95% chance of elimination of macrolide resistance by intra-species
competition alone.
Conclusions: Although it is quite possible that the fitness cost of macrolide resistance is sufficient to ensure its eventual
elimination in the absence of antibiotic selection, this process takes time, and prevention is likely the best policy in the fight
against resistance.
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Introduction
Streptococcus pneumoniae is the leading cause of serious illness in
children and adults worldwide [1]. Despite the availability of a
vaccine to combat the disease, rates of colonization remain high,
as vaccine-induced immunity often results in replacement of
targeted strains as other pneumococcal serotypes fill the newly
opened ecological niche [2]. This antigenic diversity renders
eradication nearly impossible, emphasizing the importance of
antibiotic treatment for control of invasive pneumococcal disease,
and illuminating the necessity for understanding and predicting
long-term trends in resistance.
The diversity and adaptability of S. pneumoniae is facilitated in
large part by active DNA import and extensive genomic repeats
that greatly increase the likelihood of intra- and interspecific
homologous recombination [3]. Considering its high genomic
plasticity, it is not surprising that substantial levels of drug
resistance are observed in this organism in response to antibiotic
treatment [4]. Yet, recent research has suggested that antibiotic
resistance may come at a cost to bacteria harboring the trait,
limiting fitness in the absence of antimicrobial drug selection [5].
Competition studies both in vitro [6,7,8] and in animal models
[9,10,11] have found evidence for a competitive disadvantage
from drug resistance in a range of bacterial species. At the
epidemiologic level, several observational studies have demon-
strated that lower antibiotic prescription rates are associated with
reduced antibiotic resistance [12,13]. Others have used correla-
tions between resistance and prevalence to estimate fitness costs,
either directly [14,15] or by fitting a mathematical transmission
model [16]. To our knowledge, however, no prior study has
observed the development of antibiotic resistance upon introduc-
tion of a previously unused antibiotic class, and followed the decay
of that resistance after antibiotic pressure is removed.
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Longitudinal trial data
Presented in Figure 1A is the village-level prevalence of
azithromycin-resistant strains during the course of the study, with
average prevalence superimposed. These average values have
been presented previously by our group [17]. Briefly, average
macrolide resistance rose from 28.2% after 4 treatments to 76.8%
after the 6th treatment. Resistance then declined sharply to 30.6%
at 12 months after the last antibiotic treatment, and finally to
20.8% one year after that.
To estimate baseline antibiotic resistance, we analyzed baseline
data from eight of the control villages that were within a 5 mile
radius of the intervention sites. Laboratory testing found only one
resistant case among 112 pneumococcal isolates, a rate of appro-
ximately 0.9%. Combined with survey data showing that macro-
lides constituted approximately 0.5% of the antibiotic doses
dispensed locally (B. Ayele, unpublished data), it is likely that
baseline rates of azithromycin resistance were comparably low in
intervention villages. For illustrative purposes, this assumption is
included in Figure 1A with an error bar to represent its uncer-
tainty, and an asterisk to distinguish it from directly observed data.
Figures 1B and 1C, respectively, show the proportion of
azithromycin resistance due to the mefA/E and ermB phenotypes.
We observed that pneumococcal strains harboring the mefA/E
gene constituted a larger share of azithromycin-resistant samples
than strains with the ermB phenotype. In addition, we observed
that from month 42 to month 54, the overall decrease in
azithromycin resistance was mostly due to the decrease in
prevalence of mefA/E strains. In fact, in one village, we saw the
measured prevalence of ermB strains increase from 0% to over
20% in one year. This suggests that reintroduction events played a
role in long-term transmission dynamics, and in future studies,
should be considered when feasible.
Fitness cost estimation
Our model calculated the fitness of the mefA/E phenotype to be
0.86 (95% CI 0.80 to 0.90) relative to the azithromycin-sensitive
strain, and similarly to be 0.88 (95% CI 0.82 to 0.93) for the ermB
phenotype (log likelihood~{181). Table 1 demonstrates the
sensitivity of these estimates to model inputs. Relative fitness
estimates were insensitive to nearly all fixed parameters, with the
exception of the duration of infection (1/c) and the antibiotic
efficacy against drug sensitive strains. In both cases, however,
relative fitness estimates remained significantly below one across
the range of input values tested.
Probability of Strain Survival
To examine the effect of fitness cost on predicted long-term
trends in resistance, we performed simulations extrapolating the
probability of survival for each azithromycin-resistant strain, out to
8 years after the last treatment. Figure 2 demonstrates that, under
the basecase point estimate for the relative fitness, we would expect
less than a 5% chance of survival for both drug resistant strains 5
years after the last antibiotic administration. Using the less
optimistic upper bound for this estimate, we find the probability
of survival at this time point to be only slightly higher: 6% for the
mefA/E strain, and 5.4% for the ermB strain.
Discussion
Previous research has demonstrated that antibiotic resistance
often comes with a fitness cost, the magnitude of which may
depend on growth conditions, mechanism of resistance, genetic
background, and the presence of compensatory mutations [5]. In
vitro and animal model experiments are capable of analyzing the
influence of these variables, but in humans, even quantifying an
average fitness cost of drug resistance is made difficult by the
increased complexity and decreased control introduced by
working with field data. As a result, most epidemiological studies
interested in the fitness cost of drug resistance in S. pneumoniae have
looked at correlations between naturally occurring changes in
prescription rates and the prevalence of corresponding antibiotic
resistances [14,18]. Although this has demonstrated a significant
relationship between the two factors, lack of an underlying trans-
mission model and relatively small changes in antibiotic con-
sumption have hindered the estimation of relative fitness values.
In this study, we have used data gathered as part of a
longitudinal trachoma elimination study to examine the fitness cost
of macrolide resistance in S. pneumoniae. Observed macrolide
resistance rates rose from 28.2% following four rounds of biannual
mass antibiotic distribution, to 76.8% after two subsequent rounds,
followed by a drop to 20.6% twenty-four months after the
conclusion of the program. Fitting a mathematical model to these
data, we estimated the relative fitness for strains harboring two
Figure 1. The prevalence of pneumococcal azithromycin resistance by village in the Ethiopian trachoma elimination study. A.) The
overall prevalence of azithromycin resistance. Dotted lines denote extrapolation to estimated baseline levels of resistance based on a prevalence of
resistance of 0.8% in control villages. Uncertainty in this estimate is represented with an error bar, and distinguished from observed data with an
asterisk. Arrows mark times at which community-wide antibiotic treatment took place. B.) The prevalence of ermB-mediated azithromycin resistance
C.) The prevalence of mefA/E-mediated azithromycin resistance.
doi:10.1371/journal.pone.0029407.g001
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these estimates may depend on assumed transmission parameters
and antibiotic effectiveness. Calculated fitness costs increased
significantly with higher antibiotic efficacy against drug-sensitive
strains, and longer durations of infection (1/c). These results agree
with theory. Respectively, a larger available ecological niche, or
fewer infection cycles, would both be expected to magnify the
competitive disadvantage of drug resistance given identical data.
The clinical significance of these differing fitness costs can be
measured, in part, by antibiotic-resistant strains’ probability of
survival versus time. Our model predicts that, in the base scenario,
it may take up to 5 years for macrolide resistant strains of S.
pneumoniae to reach high probabilities of elimination by competi-
tion alone. In fact, this number may be an underestimate of the
true value, as our model does not allow for the stable coexistence
of pneumococcal strains. Previous modeling studies have shown
that coexistence can be explained by simultaneous carriage of
multiple strains [19], a phenomenon we were unable to model due
to a lack of data on superinfection. However, the decreased
complexity of the model allowed us to follow the probability of all
community-level infection states over time, better capturing the
stochastic effects that are important in small populations.
It should also be noted that due to bias inherent in our
phenotyping method, any individual strains with both mechanisms
of resistance would be classified as ermB by our protocol. A study
from a different area of Ethiopia observed these strains to
constitute 6.6% of resistant samples after 4 rounds of azithromycin
treatment [20]. This misclassification would most likely increase
the estimated fitness cost for the ermB strain, although low
prevalence of mefA/E+, ermB+ strains would attenuate this effect.
In addition, our model does not allow for strain reintroduction,
or for the amelioration of fitness costs by compensatory mutation,
an adaptation that has been observed to develop quickly in other
organisms [5]. The rate of compensatory mutation is only one part
of the picture, however. In pneumococcal, both mechanisms of
macrolide resistance are mediated by entire genes rather than
single nucleotide polymorphisms (SNPs). As a result, the genetic
target for mutations that attenuate or even eliminate resistance is
comparatively much larger, consequently making these events far
more likely. In other words, in the absence of antibiotic selection
against pneumococcus, we would expect to see two opposing
effects not captured in our model. Mutation could reduce
antibiotic resistance, as well as the fitness cost associated with it.
Notwithstanding uncertainty in the long-term prediction of
resistance rates, the existence of an epidemiologically verified
fitness cost of macrolide resistance in S. pneumoniae suggests that
intraspecific competition may be exploited to at least partially
reclaim antibiotic efficacy after the development of high levels of
Table 1. Parameter ranges tested during univariate sensitivity analysis, and their influence on calculated relative fitness.
Sensitivity analysis
Parameter Baseline value Range tested Relative Fitness Log-likelihood
mefA/E ermB
Duration of infection (1/c) in weeks 8 .74 [.69–.80] .78 [.71–.84] 2162
6 .79 [.74–.85] .82 [.76–.88] 2166
2 .93 [.89–.97] .94 [.90–.98] 2250
Sensitive strain transmission rate constant (bs) 3.25 2.5 .86 [.81–.90] .88 [.83–.93] 2184
4 .85 [.81–.91] .87 [.83–.93] 2184
Antibiotic coverage*efficacy for drug sensitive strains (%) 88 70 .90 [.85–.95] .92 [.87–.97] 2178
99 .76 [.72–.81] .79 [.74–.84] 2269
Antibiotic coverage*efficacy for mefA/E strains (%) 5 1 .85 [.80–.90] .88 [.82–.93] 2182
10 .86 [.81–.91] .87 [.82–.93] 2182
Antibiotic coverage*efficacy for ermB strains (%) 5 1 .86 [.81–.90] .87 [.82–.92] 2182
10 .86 [.81–.90] .88 [.83–.93] 2183
Units for bs are per infective, per susceptible, per week.
doi:10.1371/journal.pone.0029407.t001
Figure 2. The probability of survival versus time under the basecase model for A.) the mefA/E strain and B.) the ermB strain. Upper
and lower dashed lines, respectively, correspond to the probability of survival under the upper and lower bounds of the relative fitness estimate.
doi:10.1371/journal.pone.0029407.g002
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variable and take years even under the most optimistic scenarios.
Although it is quite possible that the fitness cost of macrolide
resistance is sufficient to ensure its eventual elimination in the
absence of antibiotic selection, this process takes time, and
prevention is likely the best policy in the fight against resistance.
Methods
The Trachoma Elimination Follow-up Study
The Trachoma Elimination Follow-up (TEF) study [21] is a
longitudinal cohort study conducted in the Gurage Zone in
Ethiopia, in which 40 villages were chosen from the Gurage Zone
in Ethiopia, assessed for ocular chlamydial infection, randomized
to one of 5 treatment protocols, and monitored over a 54 month
period. Individuals aged 1 year or older were offered directly
observed treatment with single-dose oral azithromycin (1 g in
adults; 20 mg/kg in children). Pregnant women or those allergic to
macrolides were ordered a six-week course of topical 1%
tetracycline ointment to be applied twice daily to both eyes (not
directly observed).
A subset of 8 villages was selected randomly selected from the
biannual treatment arm for a more detailed pneumococcal anti-
biotic resistance investigation. During the follow-up, we collected
pneumococcal samples from fifteen randomly chosen one-to-five
year olds in each village (a total of 120 children were studied at
each time point). Nasopharyngeal swabs were taken at 24, 36, 42,
and 54 months. To estimate pneumococcal prevalence prior to
treatment, 240 children (also aged 1–5 years old) were randomly
selected and sampled from sixteen nearby villages prior to the
enrollment of the villages in the treatment program.
Verbal consent was obtained from the guardians of all children
participating in the study. Written consent was not sought due to
the low literacy rate in the area. Verbal consent was approved by
both the University of California, San Francisco Institutional
Review Board (IRB), and the Ethiopian IRB (The Ethiopian
Science and Technology Commission). Consent was documented
on the encounter form by a check mark. Approval for the study as
a whole was also obtained from the UCSF IRB and the Ethiopian
IRB. The study was carried out in accordance with the
Declaration of Helsinki.
Determining Strain Assignments
Fifteen samples were collected from each village at each time
point, tested for resistance to a variety of antibiotics, and then
classified as (1) azithromycin-sensitive (2) azithromycin-resistant,
with mefA/E phenotype or (3) azithromycin-resistant, with ermB
phenotype. All samples with mean inhibitory concentrations
(MIC) of azithromycin less than 1 mg/L where categorized as
drug-sensitive. For samples with MICs over this threshold,
individual-level antibiotic resistance profiles were used to deter-
mine the mechanism of macrolide resistance.
This inference was possible because more than 97% of
pneumococcal resistance to macrolides is mediated by one of
two genotypes [22]. Azithromycin resistance arising from the ermB
genotype also gives rise to resistance to lincosamides, such as
clindamycin [23]. In contrast, mefA/E offers no such cross-
protection, allowing for discernment between the two mechanisms
by examining whether we also observe clindamycin resistance
[24,25].
It is important to note here that our phenotyping method would
classify mefA/E+, ermB+ strains as being ermB+ only. Data from a
different area of Ethiopia showed that mefA/E+, ermB+ strains con-
stituted 6.6% of resistant strains after four rounds of azithromycin
treatment [20]. It is likely that strains carrying both resistance
alleles would have increased antibiotic resistance, but also lowered
fitness. Although our model is insensitive to the assumption of
antibiotic resistance rates for drug-resistant strains (see Table 1), it
is possible that this misclassification could amplify the estimated
fitness cost of ermB strains.
Constructing the model
We employed a dynamic SIS (susceptible-infective-susceptible)
model including mefA/E, ermB, and antibiotic-sensitive pneumo-
coccal strains, so that within each village, there was a given
number of individuals who were uninfected, infected with drug
susceptible strains, infected by mefA/E strains, and infected by
ermB strains. Between mass treatments, these numbers changed as
individuals recovered or became newly infected. During a mass
treatment, each individual’s probability of cure was the product of
the chance of treatment and the chance of cure given the
individual’s infection status. All equations relevant to this model
are included in Supporting Information S1.
The model focused on children between the ages of one and
five, as this group has the highest rates of acquisition, and new
cases within the age group appear to occur primarily as the result
of interaction with fellow members [26,27]. Based on the distances
between villages and the lack of motorized transportation in the
area, transmission between villages was assumed to be negligible.
A mixed discrete-continuous time system was used to model this
process, with ordinary differential equations (Equation A2)
governing the probability that a village has given numbers of
individuals of each status between mass treatments. The
probability of a given village state following a mass treatment
was the sum of the products of two probabilities: the probability of
being in a given state, and the probability of transitioning from
that state to the state of interest (Equation A2).
We initialized the system of equations using the first set of
available village-specific pneumococcal sample results (taken at
month 24 after the beginning of the study). Assuming a priori no
preference for any given number of individuals infected with each
of the three possible strains, we used the observed sampling results
to compute a posterior probability distribution for the number of
infected individuals in each village (see Equation A1). This
posterior distribution was used as the initial condition for data-
fitting simulations. Similarly, extrapolation of the probability of
extinction versus time was achieved by initializing the maximum
likelihood model with our observations at month 54.
In both cases, all strains were assumed to have the same rate of
recovery (c), which was extracted from the literature [28]. It should
be noted that younger children may exhibit a slower average rate
of recovery than our baseline value. As we see in the sensitivity
analysis (Table 1), the resulting longer durations of infection imply
larger proportional fitness costs, since the reduction in observed
prevalence must take place over fewer generations of transmission.
The infection rate constant for the antibiotic-sensitive strain,
bs, was calculated from the equation: equilibrium preva-
lence~1{1=R0, where R0 is the basic reproduction number.
Infection rate constants for the antibiotic-resistant strains were
allowed to vary during the optimization. In several cases, values
examined in the sensitivity analysis improved the likelihood of the
model. For the basecase, we chose to keep the parameters that we
judged to be the closest match to values from the literature.
For fitness cost estimation, cure rate parameters were also
selected for each strain to probabilistically model treatment at
months 24 and 30 (Equation A2). These values were chosen based
on survey data (B. Ayele. unpublished data), and pneumococcus-
specific pharmacodynamics simulations [29]. Comparing these
The Fitness Cost of Antibiotic Resistance
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cure rate for mefA/E of 5%. The cure rate for ermB strains was
estimated to be near-zero by this method, but was also set to 5% to
avoid introducing an ab initio difference between the two strains.
The cure rate was estimated to be 88% for the antibiotic-sensitive
strain, by extrapolating estimated treatment efficacies of around
93% from studies that used higher doses of azithromycin, but in
populations that presumably harbored resistance [30,31].
Between treatments, we integrated the ordinary differential
equations for the probability of each village state (equation A2)
using the GNU Scientific Library [32]. From these probabilities,
we used Equation A4 to calculate the likelihood function for
observing the village-level strain type data over time for each
village (taking the number of children per village to be 50,
consistent with survey results). In short, for each village we
summed over the probability of each i,j,k infection state multiplied
by the probability of our observations at that time point, given that
state. Assuming the villages to be independent, we then multiplied
these village-level probabilities together to get an overall
probability of the data at that time point given the parameters.
These time point probabilities were then multiplied together to get
the overall likelihood of the data given the parameters.
We optimized this likelihood with respect to the mefA/E and
ermB transmission rate constants, bmef and berm, using the optim
function in R (http://www.r-project.org). All other parameters
were held fixed, and subsequently examined by univariate
sensitivity analysis. Asymptotic standard errors for these estimates
were found using the observed Fisher information. Finally, the
upper bound, lower bound, and point estimates for the relative
fitness values of the mefA/E and ermB strains were used to
extrapolate each strain’s probability of survival versus time.
Supporting Information
Supporting Information S1 This file describes the equations
relevant to the construction of our model.
(PDF)
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